A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia

References

• Looney W, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 2009;9:312–23.
   PubMed Web of Science ®Google Scholar
• Sadera HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 2005;25:95–109.
   PubMedGoogle Scholar
• Zhang R, Sun Q, Hu YJ, Yu H, Li Y, Shen Q, et al. Detection of the Smqnr quinolone protection gene and its prevalence in clinical isolates of Stenotrophomonas maltophilia in China. J Med Microbiol 2012;61:535–9.
   PubMed Web of Science ®Google Scholar
• Wu H, Wang J-T, Shiau Y-R. A multicenter surveillance of antimicrobial resistance on Stenotrophomonas maltophilia in Taiwan. J Microbiol Immunol Infect 2012;45:120–6.
   PubMedGoogle Scholar
• Weiss K, Remainingieri C, De Carolis E, Laverdière M, Guay H. Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia. J Antimicrob Chemother 2000;45:363–5.
   PubMed Web of Science ®Google Scholar
• Farre DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 2010;54:2735–7.
   PubMedGoogle Scholar
• Goff DA, Kaye KS. Minocycline: an old drug for a new bug: multidrug-resistant Acinetobacter baumannii. Clin Infect Dis 2014;59(Suppl 6):365–6.
   Google Scholar
• Minocycline for injection. Available fromml: http://www.minociniv.com (accessed 3 July, 2015).
   Google Scholar
• Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013;57: 1756–62.
   PubMed Web of Science ®Google Scholar
• Kuzman I, Bezlepko A, Kondova Topuzovska I, Rókusz L, Iudina L, Marschall HP, et al. Efficacy and safety of moxifloxacin in community acquired pneumonia: a prospective, multicenter, observational study (CAPRIVI). BMC Pulm Med 2014;14:105.
   PubMedGoogle Scholar
• Conte JE Jr, Golden JA, McIver M, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects. Int J Antimicrob Agents 2006;28:114–21.
   PubMedGoogle Scholar
• Roberts JA, Kirkpatrick CMJ, Lipman J. Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother 2011;66:227–31.
   PubMed Web of Science ®Google Scholar
• Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement. CLSI document M100-S24. Clinical and Laboratory Standards Institute; 2014.
   Google Scholar
• Yamamoto T, Takano K, Matsuyama N, Koike Y, Minshita S, Sanaka M, et al. Pharmacokinetic characteristics of minocycline in debilitated elderly patient. Am J Ther 1999; 6:157–60.
   PubMedGoogle Scholar
• Andes D, Craig W. Pharmacokinetics and pharmacodynamics of tetracyclines. In: Nightingale CH, editor. Antimicrobial pharmacodynamics in theory and clinical practice, 2nd ed. Informa Healthcare; 2007 pp 267–78.
   Google Scholar
• Maaland MG, Papich MG, Turnidge J, Guardabassi L. Pharmacodynamics of doxycycline and tetracycline against Staphylococcus pseudintermedius: proposal of canine-specific breakpoints for doxycycline. J Clin Microbiol 2013; 51:3547–54.
   PubMedGoogle Scholar
• Rubino CM, Forrest A, Bhavnani SM, Dukart G, Cooper A, Korth-Bradley J, et al. Tigecycline population pharmacokinetics in patients with community or hospital-acquired pneumonia. Antimicrob. Agents Chemother 2010;54:5180–6.
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper CA, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother 2012;5:1065–72.
   Google Scholar
• Kees MG, Schaeftlein A, Haeberle HA, Kees F, Kloft C, Heininger A. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. J Antimicrob Chemother 2013;68:1331–7.
   PubMed Web of Science ®Google Scholar
• Kiffer CR, Pignatari AC. Pharmacodynamic evaluation of commonly prescribed oral antibiotics against respiratory bacterial pathogens. BMC Infect Dis 2011;11:286.
   PubMedGoogle Scholar
• Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189:1590–7.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014;14:498–509.
   PubMed Web of Science ®Google Scholar
• Gentry B, Blankinship D, Wainwright E. Oracle Crystal Ball user manual 11.1. Oracle; 2008.
   Google Scholar
• Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005;55:601–7.
   PubMed Web of Science ®Google Scholar
• Jones RN, Craig WA, Ambrose PG, Dudley MN, Pottumarthy S. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9β-lactams: adjustments of breakpoints for strains producing extended spectrum β-lactamases. Diagn Microbiol Infect Dis 2005;52:235–46.
   PubMedGoogle Scholar
• Denton M, Kerr KG. Microbiological and clinical aspects of infection caused by Stenotrophomonas maltophilia. Clin Microbiol Rev 1998;11:57–80.
   PubMed Web of Science ®Google Scholar
• Fries B, Hoover V, Wallace MR. Minocycline for treatment of Stenotrophomonas maltophilia. Abstr Intersci Conf Antimicrob Agents Chemother (ICAAC), Denver, CO, 2013. L–1335.
   Google Scholar
• Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother 2008;62:889–94.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C. Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 2010;10:287.
   PubMed Web of Science ®Google Scholar
• Tekçe YT, Erbay A, Cabadak H, Sen S. Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections. J Chemother 2012;24:150–4.
   PubMed Web of Science ®Google Scholar
• Betriu C, Rodríguez-Avial I, Sánchez BA, Gómez M, Alvarez J, Picazo JJ. Spanish Group of Tigecycline. In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2002;46:892–5.
   PubMed Web of Science ®Google Scholar
• Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999; 43:738–44.
   PubMed Web of Science ®Google Scholar
• Conte JE Jr, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005;25:523–9.
   PubMed Web of Science ®Google Scholar
• Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 1994;38:624–7.
   PubMed Web of Science ®Google Scholar
• Galles AC, Jones RN, Sader HS. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results. J Chemother 2008;20:38–42.
   PubMed Web of Science ®Google Scholar
• Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001;45:2793–7.
   PubMed Web of Science ®Google Scholar